FGFR3 and transitional cell carcinoma: In another phase I trial BGJ398 also showed evidence of clinical activity in patients with solid tumors harboring FGFR aberrations, including 4 of 5 patients with urothelial cell carcinomas (4 of which originated in the bladder) with FGFR3-activating mutations.